Erastin is a compound that interacts with VDAC, blocked and reversed mitochondrial depolarization after microtubule destabilizers in intact cells and antagonized tubulin-induced VDAC blockage in planar bilayers.

11R-VIVIT TFA is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT TFA can be used for the research of podocyte and diabetic nephropathy.

A stable, orally active, non-prostanoid prostacyclin I2 (PGI2) mimetic and prostacyclin agonist with inhibitory activity against thromboxane A2 synthase.

A fourth-generation synthetic fluoroquinolone, broad-spectrum antibacterial agent that is active against both Gram-positive and Gram-negative bacteria.

ALE-0540 is a nerve growth factor (NGF) antagonist that inhibits the binding of NGF to TrkA or both p75 and TrkA with IC50 of 5.88 and 3.72 uM, respectively.

PF-06279794, also known as PF-794, is a potent, selective and ATP-competitive TNIK inhibitor.

JTE 013 is a potent and selective S1P2 antagonist with IC50 of 17.6 nM.

SF 2312 is a highly potent, low-nanomolar inhibitor of Enolase with IC50 of 37.9 nM and 42.5 nM for recombinant hENO1 and hENO2 respectively.

G6PD activator AG1 (AG1) is a specific, small molecule that increases the activity of the wild-type, Canton mutant (R459L, EC50=3 uM) and several other common G6PD mutants; displays no effect on the dimerization or activity of several other NAD- or NADP+-dependent dimeric or tetrameric enzymes, including 6PGD, GAPDH, ALDH2, and ALDH3A1; attenuates ROS-induced pericardial edema in a G6PD-dependent manner in zebrafish, reduces hemolysis of human erythrocytes

L-Hexanoylcarnitine is an acylcarnitine and is found to be associated with celiac disease.

A peptide corresponding partly to the amino terminus of the Aα chain and Bβ chain of fibrin.

GAPDS is a small molecule that targets the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

aTAG 2139 (CFT-2139) is an aTAG-based MTH1 fusion protein degrader with a DC50 value of 1.1 nM. aTAG 2139 has a Ki value of 2.1 nM for MTH1.

T5910047 (T-5910047) is a small molecule inhibitor of MyD88-dependent signaling pathways, disrupts MyD88 homodimeric formation; inhibits SEB-induced inhibition of cytokine production in PBMCs with IC50 of 2-10 uM, also inhibits SEA-induced pro-inflammatory cytokine production, shows no toxicity in primary cells up to 100 uM.

A potent, competitive antagonist for μ, κ, δ, and σ-opioid receptors with Ki of 0.0825 nM, 0.509 nM, and 8.02 nM, for MOR, KOR, and DOR, respectively.

CEP-11981 is a potent, multi-targeted, orally active, pan-VEGFR, TIE-2 and FGFR1 inhibitor with IC50 of 3-100 nM.

A viral RNA-dependent RNA polymerase (RdRp) inhibitor that acts as a non-obligate RNA chain terminator.

Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

AEBSF HCl is a broad spectrum, irreversible serine protease inhibitor.

L-p-Bromotetramisole is a cell-permeable inhibitor of all four human AP isoenzymes (Kis =18 and 56 μM for PLAP and NSAP, respectively).

Leupeptin is a protease inhibitor, will strongly inhibit Trypsin, Papain, Plasmin, Thrombokinase, Kallikrein and Cathepsin B. The half-maximal inhibitory concentration ranges from 0.5 to 75 μg/ml, depending on the enzyme and the substrate. Leupeptin does not inhibit Chymotrypsin, Elastase, Renin, or Pepsin.

Calcein is a fluorescent dye that is useful for testing cell viability and for short-term labeling of cells.

Indocyanine Green, also known as Cardio-Green and Fox, is a tricarbocyanine dye that is used diagnostically in liver function tests and to determine blood volume and cardiac output.

D-Luciferin is a chemiluminescent substrate of firefly luciferase.

E-64 is a natural, potent, and irreversible inhibitor of cysteine proteases; IC50 values for inhibiting cathepsins K, S, and L, in vitro, are 1.4, 4.1, and 2.5 nM, respectively.

Nemorubicin, also known as PNU152243A, is a doxorubicin derivative that differs significantly from its parent drug in terms of spectrum of antitumor activity, metabolism and toxicity profile. The drug is active on tumors resistant to alkylating agents, topoisomerase II inhibitors and platinum derivatives. It works primarily through topoisomerase I inhibition. Of note, Nemorubicin is active in cells with upregulation of the nucleotide excision repair (NER) pathway, where current therapies fail. Nemorubicin is biotransformed in the liver into cytotoxic metabolites that may further contribute to render this drug highly active against primary liver tumors or liver metastases.

Tazobactam inhibits the action of bacterial β-lactamases, especially those belonging to the SHV-1 and TEM groups. It is commonly used as its sodium salt, tazobactam sodium. Tazobactam is combined with the extended spectrum β-lactam antibiotic piperacillin in the drug piperacillin/tazobactam, one of the preferred antibiotic treatments for nosocomial pneumonia caused by Pseudomonas aeruginosa.[medical citation needed] Tazobactam broadens the spectrum of piperacillin by making it effective against organisms that express β-lactamase and would normally degrade piperacillin. Tazobactam is derived from the penicillin nucleus and is a penicillinic acid sulfone.

Rimegepant (BMS-927711) is a highly potent, oral calcitonin gene-related peptide (CGRP) receptor antagonist with a Ki value of 0.027 nM.

Puromycin Dihydrochloride is an antibiotic. It inhibits protein synthesis by binding to RNA. Puromycin Dihydrochloride has antimicrobial, antitrypanosomal, and antineoplastic properties.

Puromycin is an aminoglycoside antibiotic isolated from the bacterium Streptomyces alboniger. It is a protein synthesis inhibitor.